As a biotech firm in final translational development for a revolutionary colon cancer vaccine, Vaccinogen came to idfive because it needed to be able to communicate the value of its product to the investment community.
In order to raise the funding needed for a Phase IIIb clinical trial and to expand their business, Vaccinogen needed a web site that would both attract investments and keep investors informed of Vaccinogen's progress. Additionally, Vaccinogen needed a platform to communicate with the financial services press and the investment analyst community in order to keep them abreast of their progress.
idfive created a web site that could serve all of the company's audiences. For potential investors, the media, and the analyst community, the site was designed to provide an overview of Vaccinogen's immunotherapy product, the progress it was making towards approval in the US, and its international expansion. In addition to the public face of the site, idfive created an extranet so that investors could log in to their own private areas for confidential communications and proprietary reports. Since the site launched, Vaccinogen has continued to attract new investors. Current investors have been impressed and extremely satisfied with the instant access to information offered on the company extranet.